Production (Stage)
REGENXBIO Inc.
RGNX
$10.35
$1.5016.95%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 156.72M | 83.33M | 84.33M | 89.04M | 86.73M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 156.72M | 83.33M | 84.33M | 89.04M | 86.73M |
| Cost of Revenue | -13.21M | -10.60M | -24.13M | -20.37M | -20.70M |
| Gross Profit | 169.93M | 93.93M | 108.45M | 109.42M | 107.43M |
| SG&A Expenses | 73.68M | 71.62M | 74.95M | 78.61M | 83.45M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 914.00K | 865.00K | 150.00K | 333.00K | 330.00K |
| Total Operating Expenses | 314.07M | 314.57M | 324.41M | 332.01M | 346.76M |
| Operating Income | -157.36M | -231.25M | -240.08M | -242.96M | -260.03M |
| Income Before Tax | -157.69M | -227.10M | -238.96M | -241.23M | -260.30M |
| Income Tax Expenses | -- | -- | -152.00K | -152.00K | -152.00K |
| Earnings from Continuing Operations | -157.69 | -227.10 | -238.81 | -241.08 | -260.15 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -157.69M | -227.10M | -238.81M | -241.08M | -260.15M |
| EBIT | -157.36M | -231.25M | -240.08M | -242.96M | -260.03M |
| EBITDA | -141.37M | -215.03M | -223.55M | -226.02M | -242.71M |
| EPS Basic | -3.11 | -4.61 | -5.03 | -5.27 | -5.88 |
| Normalized Basic EPS | -1.94 | -2.85 | -3.07 | -3.21 | -3.59 |
| EPS Diluted | -3.11 | -4.61 | -5.04 | -5.27 | -5.88 |
| Normalized Diluted EPS | -1.94 | -2.85 | -3.07 | -3.21 | -3.59 |
| Average Basic Shares Outstanding | 203.63M | 198.01M | 191.14M | 184.28M | 177.21M |
| Average Diluted Shares Outstanding | 203.71M | 198.01M | 191.14M | 184.28M | 177.21M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |